Cargando…

Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis

Osteoprotegerin (OPG) is a potential biomarker of cardiovascular disease complications and severity. Peripheral arterial disease (PAD) is associated with an increased risk of death in patients on peritoneal dialysis (PD). Therefore, this study aimed to evaluate the relationship between serum OPG lev...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Wei-Chen, Tsai, Jen-Pi, Lai, Yu-Hsien, Lin, Yu-Li, Kuo, Chiu-Huang, Wang, Chih-Hsien, Hsu, Bang-Gee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006676/
https://www.ncbi.nlm.nih.gov/pubmed/31950864
http://dx.doi.org/10.1080/0886022X.2020.1714654
_version_ 1783495195400077312
author Lin, Wei-Chen
Tsai, Jen-Pi
Lai, Yu-Hsien
Lin, Yu-Li
Kuo, Chiu-Huang
Wang, Chih-Hsien
Hsu, Bang-Gee
author_facet Lin, Wei-Chen
Tsai, Jen-Pi
Lai, Yu-Hsien
Lin, Yu-Li
Kuo, Chiu-Huang
Wang, Chih-Hsien
Hsu, Bang-Gee
author_sort Lin, Wei-Chen
collection PubMed
description Osteoprotegerin (OPG) is a potential biomarker of cardiovascular disease complications and severity. Peripheral arterial disease (PAD) is associated with an increased risk of death in patients on peritoneal dialysis (PD). Therefore, this study aimed to evaluate the relationship between serum OPG levels and PAD by measuring the ankle-brachial index (ABI) of patients on PD. A commercial enzyme-linked immunosorbent assay kit was used to measure OPG values. Left or right ABI values of <0.9 were categorized as the low ABI group. Among 70 patients on PD, 13 (18.6%) were categorized in the low ABI group. Patients in the low ABI group had higher prevalence of diabetes mellitus (p = .044) and higher serum C-reactive protein (CRP) (p < .001) and OPG levels (p < .001) but lower creatinine (p = .013) and peritoneal Kt/V (p = .048) levels than those in the normal ABI group. Results of multivariable logistic regression analysis revealed that OPG [adjusted odds ratio (aOR) 1.027, 95% confidence interval (CI) 1.010–1.045, p = .002] and CRP (aOR 1.102, 95% CI 1.006–1.207, p = .037) levels were independent predictors of PAD in patients on PD. OPG can also be used to predict PAD development with the area under the receiver operating characteristic curve of 0.823 (95% CI: 0.714–0.904, p < .001) in patients on PD. Therefore, serum OPG and CRP levels can be considered as risk factors for PAD development in patients on PD.
format Online
Article
Text
id pubmed-7006676
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-70066762020-02-20 Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis Lin, Wei-Chen Tsai, Jen-Pi Lai, Yu-Hsien Lin, Yu-Li Kuo, Chiu-Huang Wang, Chih-Hsien Hsu, Bang-Gee Ren Fail Clinical Study Osteoprotegerin (OPG) is a potential biomarker of cardiovascular disease complications and severity. Peripheral arterial disease (PAD) is associated with an increased risk of death in patients on peritoneal dialysis (PD). Therefore, this study aimed to evaluate the relationship between serum OPG levels and PAD by measuring the ankle-brachial index (ABI) of patients on PD. A commercial enzyme-linked immunosorbent assay kit was used to measure OPG values. Left or right ABI values of <0.9 were categorized as the low ABI group. Among 70 patients on PD, 13 (18.6%) were categorized in the low ABI group. Patients in the low ABI group had higher prevalence of diabetes mellitus (p = .044) and higher serum C-reactive protein (CRP) (p < .001) and OPG levels (p < .001) but lower creatinine (p = .013) and peritoneal Kt/V (p = .048) levels than those in the normal ABI group. Results of multivariable logistic regression analysis revealed that OPG [adjusted odds ratio (aOR) 1.027, 95% confidence interval (CI) 1.010–1.045, p = .002] and CRP (aOR 1.102, 95% CI 1.006–1.207, p = .037) levels were independent predictors of PAD in patients on PD. OPG can also be used to predict PAD development with the area under the receiver operating characteristic curve of 0.823 (95% CI: 0.714–0.904, p < .001) in patients on PD. Therefore, serum OPG and CRP levels can be considered as risk factors for PAD development in patients on PD. Taylor & Francis 2020-01-17 /pmc/articles/PMC7006676/ /pubmed/31950864 http://dx.doi.org/10.1080/0886022X.2020.1714654 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Lin, Wei-Chen
Tsai, Jen-Pi
Lai, Yu-Hsien
Lin, Yu-Li
Kuo, Chiu-Huang
Wang, Chih-Hsien
Hsu, Bang-Gee
Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis
title Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis
title_full Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis
title_fullStr Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis
title_full_unstemmed Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis
title_short Serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis
title_sort serum osteoprotegerin level is positively associated with peripheral artery disease in patients with peritoneal dialysis
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006676/
https://www.ncbi.nlm.nih.gov/pubmed/31950864
http://dx.doi.org/10.1080/0886022X.2020.1714654
work_keys_str_mv AT linweichen serumosteoprotegerinlevelispositivelyassociatedwithperipheralarterydiseaseinpatientswithperitonealdialysis
AT tsaijenpi serumosteoprotegerinlevelispositivelyassociatedwithperipheralarterydiseaseinpatientswithperitonealdialysis
AT laiyuhsien serumosteoprotegerinlevelispositivelyassociatedwithperipheralarterydiseaseinpatientswithperitonealdialysis
AT linyuli serumosteoprotegerinlevelispositivelyassociatedwithperipheralarterydiseaseinpatientswithperitonealdialysis
AT kuochiuhuang serumosteoprotegerinlevelispositivelyassociatedwithperipheralarterydiseaseinpatientswithperitonealdialysis
AT wangchihhsien serumosteoprotegerinlevelispositivelyassociatedwithperipheralarterydiseaseinpatientswithperitonealdialysis
AT hsubanggee serumosteoprotegerinlevelispositivelyassociatedwithperipheralarterydiseaseinpatientswithperitonealdialysis